Who
Richard William Scalzo
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Crescent Biopharma; SVP, Head of Finance & Admin., Dyne Therapeutics.
In numbers
- Trades disclosed
- 90
- Buys
- 0
- Sells
- 34
- Bought
- $0
- Sold
- $8.8M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 Sep 2020
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $10K568 at $17.90 | filing |
| 16 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $10K568 at $17.90 | filing |
| 22 Jun 2026filed 23 Jun 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $20K1,112 at $17.99 | filing |
| 22 Jun 2026filed 23 Jun 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $20K1,112 at $17.99 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,688 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | —14,422 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | —5,000 | filing |
| 11 Mar 2025filed 13 Mar 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K1,343 at $11.38 | filing |
| 5 Mar 2025filed 7 Mar 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K917 at $11.83 | filing |
| 18 Feb 2025filed 18 Feb 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $35K2,488 at $13.95 | filing |
| 11 Dec 2024filed 11 Dec 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K1,455 at $28.12 | filing |
| 4 Dec 2024filed 6 Dec 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,300 at $0.00 | filing |
| 4 Dec 2024filed 6 Dec 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,700 at $0.00 | filing |
| 18 Nov 2024filed 18 Nov 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K2,735 at $28.20 | filing |
| 18 Sep 2024filed 19 Sep 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K1,390 at $34.55 | filing |
| 11 Sep 2024filed 11 Sep 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $47K1,468 at $31.89 | filing |
| 6 Sep 2024filed 10 Sep 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,502 at $0.00 | filing |
| 6 Sep 2024filed 10 Sep 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,353 at $0.00 | filing |
| 6 Sep 2024filed 10 Sep 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —34,833 at $0.00 | filing |
| 6 Sep 2024filed 10 Sep 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,696 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.